Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 심현보 | * |
dc.date.accessioned | 2018-12-07T16:30:36Z | - |
dc.date.available | 2018-12-07T16:30:36Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1837-9664 | * |
dc.identifier.other | OAK-20853 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247366 | - |
dc.description.abstract | Aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) works as potent tumor suppressor, while its splicing variant lacking exon 2 (AIMP2-DX2) competes with AIMP2 for binding to target proteins and compromises its anti-tumor activity. Assuming that AIMP2 and its variant AIMP2-DX2 could be released out to human sera in pathological condition, we investigated the diagnostic and prognostic usefulness of autoantibodies against AIMP2 and AIMP2-DX2 by measuring their serum levels in 80 normal and lung cancer samples that were matched in age, gender and smoking status. The area under the curve of AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibody ratio was low (0.416, 0.579, and 0.357, respectively), suggesting limited diagnostic value. A total of 165 lung cancer patients were classified into low and high AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 based on the median expression of each parameter. The high AIMP2-DX2 group was older and had larger tumors (>3 cm) than the low AIMP2-DX2 group. The high AIMP2-DX2/AIMP2 group had higher CYFRA-21 levels and significantly shorter overall survival than the low AIMP2-DX2/AIMP2 group (18.6 vs. 48.9 months, P = 0.021, Log Rank Test). Taken together, autoantibodies against AIMP2-DX2 and AIMP2 are detectable in the human blood and the increased ratio of AIMP2-DX2/AIMP2 is related to poor clinical outcome of lung cancer. © Ivyspring International Publisher. | * |
dc.language | English | * |
dc.publisher | Ivyspring International Publisher | * |
dc.subject | Aminoacyl t-RNA synthetase (ARS) | * |
dc.subject | Aminoacyl t-RNA synthetase-interacting multi-functional protein 2 (AIMP2) | * |
dc.subject | Aminoacyl t-RNA synthetase-interacting multi-functional protein 2-exon 2 deletion (AIMP2-DX2) | * |
dc.subject | Autoantibody | * |
dc.subject | Lung cancer | * |
dc.title | Ratio of autoantibodies of tumor suppressor AIMP2 and its oncogenic variant is associated with clinical outcome in lung cancer | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1347 | * |
dc.relation.lastpage | 1354 | * |
dc.relation.journaltitle | Journal of Cancer | * |
dc.identifier.doi | 10.7150/jca.18450 | * |
dc.identifier.wosid | WOS:000402474600004 | * |
dc.identifier.scopusid | 2-s2.0-85019936256 | * |
dc.author.google | Jung J.Y. | * |
dc.author.google | Kim E.Y. | * |
dc.author.google | Kim A. | * |
dc.author.google | Chang J. | * |
dc.author.google | Kwon N.H. | * |
dc.author.google | Moon Y. | * |
dc.author.google | Kang E.J. | * |
dc.author.google | Sung J.S. | * |
dc.author.google | Shim H. | * |
dc.author.google | Kim S. | * |
dc.author.google | Chang Y.S. | * |
dc.contributor.scopusid | 심현보(26635827900) | * |
dc.date.modifydate | 20240123110611 | * |